Core Viewpoint - Saito Bio has announced a projected net loss for the year 2025, indicating significant financial challenges ahead due to various factors affecting its operations [1] Financial Performance - The company expects a net loss attributable to shareholders of between 63 million and 88 million yuan for the year 2025 [1] - The projected net loss, excluding non-recurring items, is anticipated to be between 66 million and 91 million yuan [1] Reasons for Performance Change - A decline in product market prices has led to a year-on-year decrease in overall gross margin, resulting in reduced gross profit [1] - As a high-tech biotechnology company focused on research and development, Saito Bio has increased its R&D expenditures, contributing to the decrease in net profit for the reporting period [1] - The company has recognized significant inventory impairment provisions for several intermediate products due to falling product prices, which has negatively impacted current profits [1]

Core Viewpoint - The company expects a net profit loss of 63 to 88 million yuan for the fiscal year 2025 due to declining product prices and increased R&D expenses [1] Group 1: Financial Performance - The overall gross profit margin of the company's products has decreased year-on-year due to falling market prices [1] - The company has increased its R&D investment during the reporting period, contributing to the reduction in net profit [1] - Significant inventory impairment provisions were made for several intermediate products due to price declines, impacting current profits [1]

证券代码：300583 证券简称：赛托生物 公告编号：2026-004 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净利润 | 亏损：6,300-8,800 | 亏损：8,876.67 | | 扣除非经常性损益后的净利润 | 亏损：6,600-9,100 | 亏损：10,336.12 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计，但公 司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本 次业绩预告方面不存在重大分歧。 三、业绩变动原因说明 山东赛托生物科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 五、备查文件 董事会关于本期业绩预告的情况说明。 特此公告。 山东赛托生物科技股份有限公司 董事会 本报告期业绩变动的主 ...

Group 1 - The company, Saito Bio, indicated that the disclosure date for the 2025 performance forecast will be based on the company's official announcements [2] - The company emphasized its commitment to production and operations to reward investors' trust through performance [2]

每经AI快讯，赛托生物(300583)1月20日公告，控股子公司斯瑞药业近日收到欧洲药品质量管理局签发 的原料药欧洲药典适用性证书（简称"CEP证书"），获证化学原料药名称为糠酸氟替卡松，该药品是一 种强效的糖皮质激素，用于鼻喷剂，可治疗2岁及2岁以上季节性和常年性过敏性鼻炎；用于吸入粉雾 剂，可治疗哮喘和慢性阻塞性肺疾病(COPD)。 （文章来源：每日经济新闻） ...

Core Viewpoint - Saito Bio (300583.SZ) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for its active pharmaceutical ingredient, fluticasone propionate [1] Group 1: Company Developments - The receipt of the CEP certificate is a significant milestone for Saito Bio, as it validates the quality of its fluticasone propionate product for use in Europe [1] - Fluticasone propionate is a potent glucocorticoid used in nasal sprays to treat seasonal and perennial allergic rhinitis for patients aged 2 years and older, and in inhalation powder for the treatment of asthma and chronic obstructive pulmonary disease (COPD) [1]

证券代码：300583 证券简称：赛托生物 公告编号：2026-003 糠酸氟替卡松是一种强效的糖皮质激素，用于鼻喷剂，可治疗 2 岁及 2 岁以 上季节性和常年性过敏性鼻炎；用于吸入粉雾剂，可治疗哮喘和慢性阻塞性肺疾 病(COPD)。 公司于 2025 年 6 月向 EDQM 提交了糠酸氟替卡松（原料药）的 CEP 申请，2026 年 1 月获得 CEP 证书。EDQM 官网显示，除斯瑞药业外，全球糠酸氟替卡松原料 药生产企业中有 6 家持有有效的 CEP 证书。根据 IQVIA 数据统计，糠酸氟替卡松 原料药 2024 年全球需求量约为 500 公斤。 三、对公司的影响 公司取得糠酸氟替卡松原料药 CEP 证书，标志着公司该原料药可以在认可 CEP 证书的国际市场进行销售，将为公司糠酸氟替卡松原料药拓展国际市场带来 积极的影响，进一步丰富公司的产品线，有利于提升公司在化学原料药领域的市 场竞争力。 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简 ...

Group 1 - The core point of the article is that Saito Bio has announced the approval of a proposal regarding expected daily related party transactions by its board of directors [2] Group 2 - The announcement was made on January 16, indicating the company's ongoing governance and operational activities [2] - The board's decision reflects the company's strategy to manage its related party transactions effectively [2]

每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ （记者 贾运可） 每经AI快讯，赛托生物1月16日晚间发布公告称，公司第四届第十二次董事会会议于2026年1月16日在 公司会议室以现场结合通讯表决的方式召开。会议审议了《关于公司及子公司日常关联交易预计的议 案》等文件。 ...

证券代码：300583 证券简称：赛托生物 公告编号：2026-002 山东赛托生物科技股份有限公司 关于公司及子公司日常关联交易预计的公告 | 关联交易 | 关联人 | 关联交易 | 关联交易定价 | 合同签订金额或预 | 截至披露日已发 | 上年发生金 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | 内容 | 原则 | 计金额（万元） | 生金额（万元） | 额（万元） | | 销售商品及 | 信谊津津 | 产品 | 依照公允价格 | 2,000.00 | 488.85 | 5,089.31 | | 提供劳务 | | 小计 | | 2,000.00 | 488.85 | 5,089.31 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 山东赛托生物科技股份有限公司（以下简称"公司"）及子公司根据业务发展 及日常经营需要，预计与关联方天津信谊津津药业有限公司（以下简称"信谊津津"） 发生日常关联交易，主要为向关联方销售商品及提供劳务等，预计发生 ...